Publisher Correction: cost-effectiveness of COVID-19 vaccination in Latin America and the Caribbean: an analysis in Argentina, Brazil, Chile, Colombia, Costa Rica, Mexico, and Peru

被引：0
|
作者：
Federico Augustovski
Ariel Bardach
Adrián Santoro
Federico Rodriguez-Cairoli
Alejandro López-Osornio
Fernando Argento
Maissa Havela
Alejandro Blumenfeld
Jamile Ballivian
Germán Solioz
Analía Capula
Analía López
Cintia Cejas
William Savedoff
Alfredo Palacios
Adolfo Rubinstein
Andrés Pichon-Riviere
机构：
[1] Instituto de Efectividad Clínica y Sanitaria (IECS) - CONICET,Departamento de Evaluación de Tecnologías Sanitarias y Economía de la Salud/Health Technology Assessment and Health Economics Department, Institute for Clinical Effectiveness and Health Policy
[2] Centro de Implementación e Innovación en Políticas de Salud (CIIPS). Instituto de Efectividad Clínica y Sanitaria (IECS)/Institute for Clinical Effectiveness and Health Policy,undefined
[3] Social Insight,undefined
来源：
Cost Effectiveness and Resource Allocation | / 21卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 40 条
  • [21] Acceptance towards COVID-19 vaccination in Latin America and the Caribbean: A systematic review and meta-analysis
    Alarcon-Braga, Esteban A.
    Hernandez-Bustamante, Enrique A.
    Salazar-Valdivia, Farley E.
    Valdez-Cornejo, Valeria A.
    Mosquera-Rojas, Melany D.
    Ulloque-Badaracco, Juan R.
    Rondon-Saldana, Jenny C.
    Zafra-Tanaka, Jessica H.
    TRAVEL MEDICINE AND INFECTIOUS DISEASE, 2022, 49
  • [22] Cost-Effectiveness Analysis of Strategies of COVID-19 Vaccination in Colombia: Comparison of High-Risk Prioritization and No Prioritization Strategies With the Absence of a Vaccination Plan
    Morales-Zamora, Gilberto
    Espinosa, Oscar
    Puertas, Edwin
    Fernandez, Juan Carlos
    Hernandez, Jose
    Zakzuk, Veronica
    Cepeda, Magda
    Alvis-Guzman, Nelson
    Castaneda-Orjuela, Carlos
    Paternina-Caicedo, Angel
    VALUE IN HEALTH REGIONAL ISSUES, 2022, 31 : 101 - 110
  • [23] A cost-effectiveness analysis of South Africa's ' s COVID-19 vaccination programme
    Edoka, Ijeoma
    Silal, Sheetal
    Jamieson, Lise
    Meyer-Rath, Gesine
    VACCINE, 2024, 42 (20)
  • [24] The rise of health biotechnology research in Latin America: A scientometric analysis of health biotechnology production and impact in Argentina, Brazil, Chile, Colombia, Cuba and Mexico
    Israel Leon-de la O, Dante
    Thorsteinsdottir, Halla
    Calderon-Salinas, Jose Victor
    PLOS ONE, 2018, 13 (02):
  • [25] COVID-19 vaccination plans in Latin America and the Caribbean: a multi-country comparative analysis of prioritization strategies
    Woodbine, M. J. Hernandez
    Fernandez-Nino, J. A.
    Rodriguez-Villamizar, L. A.
    Rojas-Botero, M. L.
    PUBLIC HEALTH, 2024, 228 : 162 - 170
  • [26] Cost-Effectiveness Analysis of COVID-19 Vaccination in Low- and Middle-Income Countries
    Utami, Auliasari M.
    Rendrayani, Farida
    Khoiry, Qisty A.
    Alfiani, Fitri
    Kusuma, Arif S. W.
    Suwantika, Auliya A.
    JOURNAL OF MULTIDISCIPLINARY HEALTHCARE, 2022, 15 : 2067 - 2076
  • [27] COVID-19 and dengue co-infection in Brazil: optimal control and cost-effectiveness analysis
    A. Omame
    H. Rwezaura
    M. L. Diagne
    S. C. Inyama
    J. M. Tchuenche
    The European Physical Journal Plus, 136
  • [28] COVID-19 and dengue co-infection in Brazil: optimal control and cost-effectiveness analysis
    Omame, A.
    Rwezaura, H.
    Diagne, M. L.
    Inyama, S. C.
    Tchuenche, J. M.
    EUROPEAN PHYSICAL JOURNAL PLUS, 2021, 136 (10):
  • [29] Cost-effectiveness Analysis of COVID-19 mRNA XBB.1.5 Fall 2023 Vaccination in the Netherlands
    Zeevat, Florian
    van der Pol, Simon
    Westra, Tjalke
    Beck, Ekkehard
    Postma, Maarten J.
    Boersma, Cornelis
    ADVANCES IN THERAPY, 2025, 42 (03) : 1550 - 1569
  • [30] Cost-effectiveness analysis of COVID-19 booster vaccination with BNT162b2 in Japan
    Nagano, Mitsuhiro
    Kamei, Kazumasa
    Matsuda, Hiroyuki
    Takahashi, Chihiro
    Yang, Jingyan
    Wada, Koji
    Yonemoto, Naohiro
    EXPERT REVIEW OF VACCINES, 2024, 23 (01) : 349 - 361
1234